ARGYLE CONSULTING LIMITED

Company number SC179496 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

1. Financial Health Score

Grade: B — Good, with monitoring required.

Argyle Consulting Limited presents a generally healthy financial constitution: it is solvent, cash-rich, has positive net assets, and has rebuilt liquidity in the latest year. The score is held back from an A by three watch items: thin working capital, a large investment concentration, and limited public profitability disclosure because the small-company accounts do not include a profit and loss account. There is also evidence of balance-sheet volatility between FY2022 and FY2024, followed by a strong recovery in FY2025.

In medical terms: the patient has a strong pulse and a healthy cash reserve, but blood pressure is a little variable and the circulation is only just adequate.


2. Key Vital Signs

Vital sign Latest position (30 Nov 2025) Prior year / trend Interpretation
Net assets / shareholders’ funds £1.701m £1.091m in 2024; £3.064m in 2022 Positive and sharply recovered, but historically volatile.
Equity ratio — net assets ÷ total assets 46.9% 37.8% in 2024; 66.2% in 2022 A solid loss-absorbing cushion, though lower than the 2022 peak.
Cash at bank £1.523m £1.061m in 2024 Strong cash balance; cash rose £462.5k, or 43.6%.
Cash ratio — cash ÷ current liabilities 0.82x 0.60x in 2024 Cash alone covers 82% of short-term liabilities; improved but not a full buffer.
Current ratio — current assets ÷ current liabilities 1.02x 0.86x in 2024 Just above breakeven; working capital is thin.
Net current assets £34.9k Negative £238.5k in 2024 Returned to positive territory, but only narrowly.
Investments £1.651m £1.289m in 2024 45.5% of total assets; the largest asset class.
Cash plus investments £3.174m — 87.6% of total assets; highly liquid/financial-asset weighted, but with valuation risk.
Debtors £379k £460k in 2024 Down 17.8%; supports cash conversion, though turnover data is unavailable.
Creditors due within one year £1.867m £1.760m in 2024 Up 6.1%; the main short-term pressure point.
Provisions for liabilities £56.6k £36.7k in 2024 Small relative to net assets, but increased.
Filing compliance Accounts next due 31 Aug 2027; confirmation statement next due 6 Jun 2027 Neither overdue Healthy compliance vital sign.

What these vital signs indicate

  • Solvency is strong. Net assets of £1.701m are positive, and the equity ratio of 46.9% means the company has a reasonable cushion to absorb losses. The company is not balance-sheet insolvent on the filed figures.
  • Liquidity has improved but remains tight. Current assets of £1.902m only just exceed current liabilities of £1.867m, leaving £34.9k of net working capital. A small deterioration in debtor collection, cash outflow, or creditor pressure could push the current ratio back below 1.0x.
  • Cash generation appears strong. Cash rose substantially in the latest year, and cash represents 42.0% of total assets. However, the accounts do not include a cash flow statement in the extracted data, so it is not possible to confirm how much cash came from trading versus other balance-sheet movements.
  • The balance sheet is financial-asset heavy. Investments plus cash make up 87.6% of total assets. That is not inherently unhealthy for a financial-services/pension-funding related business, but it means reported net assets are sensitive to investment valuations, especially if the portfolio includes unlisted investments.
  • Profitability cannot be directly measured. The accounts are filed under the small-company regime and the Statement of Comprehensive Income has not been delivered. Retained earnings increased by £609.8k, which is a positive symptom, but the accounts do not allow a clean split between trading profit, investment gains, distributions, and other reserve movements.

3. Diagnosis

Overall diagnosis: stable, solvent, and recovering — but with watch items

The company’s financial “constitution” is reasonably strong. It has positive net assets, a substantial cash balance, a long operating history, and no overdue filings. The latest year shows a clear recovery: net assets increased by 55.9%, cash increased by 43.6%, and net current assets moved from negative £238.5k to positive £34.9k.

The main symptoms are not of immediate distress. They are symptoms of balance-sheet concentration and limited visibility:

  1. Thin working-capital buffer.
    The current ratio of 1.02x is technically healthy but only barely. The company relies on collecting debtors and managing creditor outflows to keep liquidity positive. Cash alone covers 82% of current liabilities, which is good, but not enough to ignore working-capital discipline.

  2. Investment concentration risk.
    Investments of £1.651m are 45.5% of total assets. The notes indicate both listed and unlisted investment categories are present. Unlisted investments can be harder to value and harder to sell quickly. A fall in investment values would directly reduce net assets and could affect the company’s reported financial strength.

  3. Historical volatility.
    Net assets fell from £3.064m in FY2022 to £1.239m in FY2023 — a decline of about 59.6% — before stabilising in FY2024 and recovering in FY2025. Total assets also fell by about 40.1% between FY2022 and FY2023. The filed small-company accounts do not provide enough detail to identify the precise cause. This is a symptom that warrants management explanation and monitoring, not an immediate red flag on its own.

  4. Profit quality is not visible.
    Retained earnings rose from £1.041m to £1.651m, a £609.8k increase. That is a strong positive. But because the profit and loss account is not publicly filed, stakeholders cannot verify whether this came from recurring trading profit, investment revaluation, asset disposals, or other movements. The quality of the surplus therefore needs confirmation from management accounts.

  5. Capital restructuring.
    Called-up share capital fell from £19,016 to £13,409, while the capital redemption reserve rose from £3,887 to £9,494. That pattern is consistent with a share buyback or cancellation. It is not a liquidity alarm in itself, but it means distributions and capital returns should be tested against retained profits and cash headroom.

Prognosis

Base case: stable with a positive outlook, provided investment values hold and working capital is actively managed.
The company has enough cash and positive net assets to remain financially stable in the near term. The recovery in FY2025 is a good sign.

Main risks to the prognosis:

  • A market or valuation downturn affecting the investment portfolio.
  • Liquidity pressure if current liabilities accelerate or debtors slow.
  • Further unexplained balance-sheet volatility.
  • Distribution or buyback activity that outpaces sustainable profits and cash generation.
  • Limited visibility over profitability and cash flow quality.

Monitoring triggers: current ratio falling below 1.0x; cash ratio falling materially below 0.8x; net assets declining by more than 10%; a significant fall in investment valuations; or any overdue filing.


4. Recommendations

  1. Build a larger working-capital buffer.
    Aim to keep cash and readily realisable investments comfortably above current liabilities. The current cash ratio of 0.82x is acceptable but not generous. A modest buffer would reduce the risk of the current ratio slipping below 1.0x.

  2. Monitor the investment portfolio closely.
    Stress-test the balance sheet for a 10–20% fall in investment values, with particular attention to unlisted holdings. Confirm valuation basis, liquidity, and concentration limits. If unlisted investments are material, consider whether the company has enough readily available cash outside that portfolio.

  3. Prepare monthly management accounts.
    Because the filed accounts omit the profit and loss account, the board should monitor turnover, gross margin, operating profit, cash flow, debtor days, creditor days, and budget variances monthly. This is the equivalent of regular blood tests: the filed accounts give the annual physical, but management accounts show the day-to-day vital signs.

  4. Maintain strict debtor and creditor discipline.
    Debtors fell 17.8%, which is encouraging, but working capital is thin. Continue prompt invoicing, credit control, and cash forecasting. Avoid relying on a single debtor or a small group of creditors to keep liquidity positive.

  5. Review capital distributions against sustainable profits and cash.
    The reduction in share capital and increase in the capital redemption reserve should be considered alongside retained earnings, cash headroom, and future investment needs. Distributions should leave enough cushion for provisions, working capital, and investment volatility.

  6. Monitor provisions and tax positions.
    Provisions rose to £56.6k. Although small relative to net assets, they should be reviewed alongside any deferred tax or investment-related tax positions.

  7. Keep compliance in good order.
    Filings are current, which is a positive governance signal. Maintain the diary for the next accounts and confirmation statement, and ensure any changes in ownership or control are notified on time.

Perspective: Financial Health Diagnostician · Model: deepseek-v4.1-flash · Generated 17 November 2026